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Summary
Purpose. — Evaluate heart failure management in a Military Hospital in 2005.
Methods. — Retrospective audit of 46 case records of patients hospitalised with heart failure
within the framework of an accreditation procedure.
Results. — The left ventricular ejection fraction was evaluated in 85% of cases during the
reference hospital stay. Systolic heart failure was detected in 63% of cases. At least one NT-
proBNP assay was performed for each patient. A global assessment was systematically
performed, except for the mini mental state examination in patients aged over 75 years who
represented 80% of patients. Initial therapeutic education was provided for 50% of systolic
heart failure patients. Prescription rates in systolic heart failure were 76% for angiotensin-
converting enzyme inhibitors, 7 % for angiotensin receptor antagonists; 84% for at least one
medicinal product in the above 2 classes; 68 % for beta-blockers and 32 % for spironolactone. A
hospital discharge report was available for 93% of the patients. Elective re-admissions to
hospital for uptitration of treatment concerned 10% of systolic heart failure patients.
Emergency hospital re-admissions after a cardiovascular event (usually decompensation),
concerned 35% of patients, after an average duration of one year of follow-up. These latter re-
admissions, often repeated, led to 4% of additional hospital deaths. The initial hospital
mortality rate was 13%.
Conclusion. — Therapeutic patient education is under development. Medication may still be
optimised, both qualitatively and quantitatively. Surveillance is planned with a yearly audit.
© 2008 Published by Elsevier Masson SAS.
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Résumé
But. — Évaluer dans un Hôpital d’Instruction des Armées en 2005, la prise en charge de
l’insuffisance cardiaque.
Méthode. — Audit rétrospectif réalisé dans le cadre d’une procédure d’accréditation de
46 dossiers de patients hospitalisés pour insuffisance cardiaque.
Résultats. — La fraction d’éjection ventriculaire gauche a été évaluée dans 85 % des cas lors
de l’hospitalisation de référence. Il s’agissait d’une insuffisance cardiaque systolique dans 63 %
des cas. Chaque patient a bénéficié d’au moins un dosage du NT-pro BNP. L’évaluation globale
a été systématique, sauf pour la réalisation du mini mental state examination chez les plus de
75 ans, représentant 80 % des patients. Une éducation thérapeutique initiale a été réalisée
pour 50 % des insuffisants cardiaques systoliques. Le taux de prescription dans l’insuffisance
cardiaque systolique des inhibiteurs de l’enzyme de conversion était de 76 %, des antagonistes
des récepteurs de l’angiotensine II : 7 %, d’au moins un médicament des 2 classes précédentes :
84 %, de béta-bloquants : 68 %, de spironolactone : 32 %. Un compte rendu d’hospitalisation
était disponible pour 93 % des patients. Les rehospitalisations programmées pour majoration
progressive du traitement ont concerné 10 % des insuffisants cardiaques systoliques. Les
rehospitalisations en urgence à l’hôpital motivées par un événement cardiovasculaire (le plus
souvent une décompensation), ont intéressé 35 % des malades, pour une durée moyenne de
suivi de un an. Ces dernières, souvent répétées, ont été à l’origine de 4 % de décès
supplémentaires dans l’institution. Le taux de mortalité hospitalière initiale était de 13 %.
Conclusion. — L’éducation thérapeutique est en cours de développement. Il reste une marge
pour l’optimisation du traitement médicamenteux, à la fois qualitative et quantitative. Une
surveillance par audit annuel est prévue.
© 2008 Published by Elsevier Masson SAS.
Introduction
Heart failure constitutes a major public health problem,
because of its prevalence, increasing with age and the ageing
of the population as well as because of difficulties in diagno-
sis particularly in elderly subjects, its accompanying morbi-
dity and mortality and the cost for society [1-7]. We were
interested in assessing heart failure management at the
Bégin Military Hospital (MH) in 2005 [8, 9] within the scope of
an accreditation procedure. Like all military hospitals, the
hospital has a public service role. Heart failure is the first
reason for admission to the cardiology department, either in
cardiology intensive care (75/355: 21% of admissions) or in
the conventional hospitalisation sector (165/937: 18%).
Methods
Design
46 medical records from patients admitted to the cardiology
department during the first six-month period of 2005 were
reviewed retrospectively after random selection (using
alphabetical lists of names obtained by using the heart
failure codes of the 10th revision of the international classifi-
cation of diseases: I50.0, I50.1, I50.9). The first six months of
the year were chosen in order to have a longer follow-up
(mean follow-up duration of 12 months [9 to 15 months]). A
single medical record was incomplete (i.e. 5%), as it had a
missing Emergency Department (ED) admission record. 
Data collected
A data collection grid was prepared according to the joint
national guidelines of the French Cardiology Society and the
French Society of Geriatrics and Gerontology published in
2004, concerning the diagnosis and management of heart
failure in elderly subjects [3] (appendix). The variables col-
lected concerned the hospital department to which the
patient was first admitted as well as clinical, paraclinical,
social, therapeutic as well follow-up data.
Analysis
A descriptive analysis of collected variables was performed.
Results
Admissions
46% of patients were admitted via the ED and 35% directly
to the cardiology department.
40% of transfers to the cardiology department were car-
ried out on the day of admission and 20% during the fol-
lowing 2 days. 
Evaluation of morbidity
Positive and differential diagnosis
A clinical examination (evaluation of dyspnoea, detection
of asthenia, peripheral oedema, alveolar and/or bronchial
ronchi, signs of right heart failure, tachycardia and an S3
ventricular gallop, advanced heart valve disease) and
conventional paraclinical investigations (ECG, chest X-ray
and measurement of SpO2 or arterial gazometry in ambient
air) were systematically performed.
Transthoracic echocardiography or equivalent (evalua-
tion of left ventricular ejection fraction [LVEF]) was
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conducted during the reference hospital stay in 85% of
patients (77% of cases during the stay in the cardiology
department).
NT-proBNP was assayed at least once in all patients (this
assay was systematically performed in the ED for patients
admitted via this department). 
Diagnosis of the type of LV dysfunction
Systolic for 63% of patients (threshold LVEF value lower
than 50%), otherwise with preserved LV systolic function or
rarely not assessed (no known systolic dysfunction or not
tested in 4% of the cases).
Aetiology and precipitating factor
These were systematically sought, at least from the clinical
and conventional paraclinical findings. There was no indivi-
dually identifiable precipitating factor in 40% of cases, par-
ticularly in advanced dilated cardiomyopathy, except that
acute coronary syndrome was more frequently observed
(17%), followed by episodes of infection (15%), poor adhe-
rence or drug misadventures (8%), atrial fibrillation (8%),
hypertensive flare-ups (8%) and anemia (8%). Coronary
disease (37%) was the main etiology, followed by high blood
pressure (24%), valve disease (16%), atrial fibrillation (13%)
and these were often present concomitantly in elderly sub-
jects.
Diagnosis of co-morbidities
The overall evaluation (of the underlying diathesis) was also
systematically performed, except for the conduct of the
mini mental state examination (MMSE) in patients aged over
75 years (80% of our patients), which was performed in 5%.
Autonomy was assessed in a standardised manner using a
questionnaire concerning food behaviour, drug compliance,
washing, toileting, transfers, assistance from care-givers or
in some cases a home aid and detection of incontinence.
The nutritional status was evaluated from dietary habits
and overall from body weight, analysis of motricity, tests
for dependence, trophic disorders (pressure sores), and in
some cases assay of serum albumin concentrations.
Social evaluation
Social data was collected on admission. A social aid file was
opened if a welfare officer intervened. 
Treatment
Institution of treatment without delay: 
in 96% of the cases, with 4% delay due to diagnostic diffi-
culties. 
Dietary and lifestyle measures 
(education, rehabilitation)
Therapeutic patient education (TPE) was provided during
the hospital stay for approximately 50% of systolic heart
failure patients, with interactive information given by a
nurse. This was systematically evaluated using a question-
naire and the patient was then given a patient diary. This
gave information about warning signs, factors of decompen-
sation, dietary-lifestyle measures and medication, self-
monitoring and laboratory monitoring procedures. Dis-
charge body weight as well as blood electrolytes, serum
creatinine and NT-proBNP levels were also recorded in the
diary. TPE was repeated where necessary (if it had been
poorly formulated). These TPE sessions were noted in the
patient's medical record. Education was sometimes restric-
ted by the elderly age (95 years and more) or dementia syn-
dromes (7% of heart failure patients). The family was then
used as a healthcare partner. Rehabilitation was rarely
used and concerned 7% of systolic heart failure patients.
Psychological support
This was sometimes provided by volunteers from palliative
care associations.
Medication
Discharge medication included angiotensin-converting
enzyme inhibitors (ACEi) for 82% of patients (76% for systo-
lic heart failure patients), angiotensin receptor antagonists
(ARA) for 7% (8% for systolic heart failure patients), and
drugs in one of these two classes for 90% (84% of systolic
heart failure patients).
Beta-blockers were prescribed in 67% of patients and 68%
of the systolic heart failure patients (who used validated
products).
Spironolactone was prescribed in 20% of patients and 32%
of systolic heart failure patients.
Patient end-of-life care was provided in accordance with
the department’s protocol. 
Surveillance and liaison
Hospital discharge report
This was available for 93% of patients. 
Hospital readmissions
Elective readmissions to hospital for uptitration of treat-
ment concerned 10% of the systolic heart failure patients.
Emergency hospital readmissions following a cardiovas-
cular event, concerned 35% of patients and were often
repeated (57%), in most cases secondary to decompensation
(71%) with a further 4% of additional deaths at the Bégin MH
(for an average follow-up duration of one year).
Mortality
The initial hospital mortality rate was 13%.
Discussion
This was a study on a small patient population, analysed
retrospectively within the framework of an evaluation of
professional practices, conducted at the time of the second
accreditation visit. This population had the usual characte-
ristics of heart failure patients: very elderly subjects inclu-
ding approximately half with systolic heart failure and a
prevalence of ischemic heart disease. Precipitating factors
were conventional, though quite often these were not indi-
vidually identifiable and then showed the advanced stage
of the cardiomyopathy [1-7]. The initial and total one-year
hospital mortality were 13% and 17% respectively in our hos-
pital, with 35% of emergency hospital readmissions. These
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data agree with what is known about acute heart failure
[7]. The SENIORS study (conducted between 2000 and 2002)
showed for a younger population than ours of heart failure
patients (systolic or with preserved LVEF) with an average
age of 75 years, an annual mortality rate in the nebivolol
arm of approximately 4% with 14% of hospital readmissions
for cardiovascular events [10]. In the MERIT-HF sub-group
of elderly subjects (age over 65 years, average age 72
years, with systolic heart failure, performed at the end of
the 1990s), after one year of follow-up the cardiovascular
death rate was 8% and the hospital readmission rate for car-
diovascular events, was 27% in the metoprolol arm, inclu-
ding approximately half because of cardiac decompensa-
tion. In a small sub-group (490 patients) aged over 74 years
in MERIT-HF, the annual death rate was 10%, with 23% of
hospital readmissions for decompensation [11]. Lastly, the
Euroheart Failure Survey registry, in 2001, for patients with
an average age of 76 years, gave an initial hospital death
rate of 6.9%; cumulative mortality at 3 months was 13.5%
and the hospital readmission rate was 24% (including
approximately 1/3 for heart failure) [12]. A Euroheart
Failure Survey sub-study showed a mortality rate of 68% in
patients aged over 75 years (vs 31% for younger patients)
after a follow-up of almost 4 years [13].
The determination of LVEF is an indicator of the quality
of the clinical evaluation [14]. Moreover the investigation
of professional practices has a higher sensitivity for analy-
zing the quality of a healthcare structure than the evalua-
tion of disease outcomes inside the same hospital [15]. In
our study, LVEF was evaluated in 85% of patients during the
audited hospital stay. Again for the Euroheart Failure Sur-
vey registry, the evaluation of LVEF was conducted in 63%
of patients in Europe and 91% in France [12]. A cross-sectio-
nal study evaluating the quality of management of heart
failure in 1999 in 3 Swiss university hospital centers
demonstrated, in addition to large centers disparities, an
evaluation of LVEF in 68% of patients [16]. Another retros-
pective study on a cohort of veteran outpatients in the USA,
performed between 2000 and 2002, evaluating racial diffe-
rences in the quality of care and prognosis showed that
LVEF was determined in 85% [17]. An evaluation of the qua-
lity of healthcare and its outcome carried out in more than
3000 accredited US hospitals, from 2002 to 2004, showed,
for heart failure, that LVEF was evaluated on average in
85% of patients (in less than 80% for the low performing
centers, between 80 and 90% for average performing cen-
ters and more than 90% in the high performing centers)
[14]. A single-center retrospective study on the quality of
care dispensed to Afro-American patients admitted for
heart failure in 2005 showed that LVEF was evaluated in
96% of patients [18]. At least one assay for NT-proBNP, ini-
tially used for diagnosis (particularly in the ED), was carried
out in all patients [19].
The recommendation concerning the MMSE in patients
aged over 75 years was not generally followed due to lack
of time but was evaluated during TPE. Systematic realisa-
tion of this examination is justified both by the fact that it
is impossible to screen for incipient impairment during the
usual clinical examination and by the insufficient reliability
of data collected during the interview in such a context [3].
The 5-word test provides another tool to diagnose impair-
ment before PTE as this screening test was designed to be
easily and widely used and has a good diagnostic value (sen-
sitivity of 63% and specificity of 91%) [20]. When this thera-
peutic patient education cannot be in an appropriate way
dispensed, the close contacts are trained instead of the
patient. 
For discharge medication, the Euroheart Failure Survey
program register showed for all types of heart failure put
together, prescription rates of 62% for ACEi (80% in systolic
heart failure), 4.5% for ARA (6% in systolic heart failure),
37% for beta-blockers (49% in systolic heart failure) and
20.5% for spironolactone (21). For the subgroup of patients
aged over 70 years, ACEi were prescribed in 58% of heart
failure patients, and beta-blockers in 30% [12]. The Swiss
study showed prescription rates of 86 % for ACEi and 21 %
for beta-blockers [16]. The study in veterans showed pres-
cription rates of 80% for ACEi, 8% for ARA and 63% for beta-
blockers, in systolic heart failure patients [17]. The evalua-
tion of the quality of care in US hospitals showed mean
prescription rates of 75% for ACEi (up to 70% in the low per-
forming centers, between 71 and 80% in average performing
centers and more than 80% in the high performing centers)
[14]. The study concerning quality of care provided to Afro-
Americans patients admitted for heart failure in 2005 gave
prescription rates of 76% for ACEi, 15 % for beta-blockers,
10% for spironolactone and these rates were 89%, 24% and
15% respectively for systolic heart failure patients [18]. A
cross-sectional survey carried out in 2005 in the French Car-
diology ICU concerning the management of post-MI heart
failure and systolic LV dysfunction showed prescription
rates of 73% for ACEi and 66% for beta-blockers [22]. These
prescriptions are particularly meaningful [23]. Mortality
was multiplied by 8 in the event of non-specialized manage-
ment and 6 in the absence of a neurohumoral blockade
[13]. The usual underdosing with ACEi and beta-blockers
was not evaluated [24].
Concerning TPE, the North-American quality study
showed that information about recommended post-dis-
charge management was given to approximately 30% of
patients in the low performing centers, close to 50% for
average performing centers and more than 70% in the high
performing centers [14]. The study of Afro-Americans
patients admitted for heart failure in 2005 showed that 50%
received advice about the importance of good adherence to
drug treatment and a low-sodium diet and 9% on daily
weighing [18]. The importance of therapeutic patient edu-
cation, including in terms of a reduction in morbidity and
mortality, is currently well documented, placing it at the
same level as well-conducted medication [25-30]. Because
of the impact of education and the unfavourable short-term
outcome of heart failure, PTE is still relevant in subjects
aged over 75 years [25, 26]. Moreover, it is ethically diffi-
cult to justify not providing information to patients about
the most essential part of their treatment, just because of
their advanced age.
The evaluation of professional practices legitimates
audit as a tool for monitoring the performance of a health-
care structure [31, 32]. In particular, it has a positive
impact on the quality of care, which is the main reason for
the accreditation procedure [33, 34]. The rate of improve-
ments is inversely correlated to the level of performence of
the center [14]. It is mainly based on feedback-information
and emulation [33, 34]. In our center, the desire for pro-
gress has made us more aware of the need to develop the-
rapeutic patient education and improve team work in order
to optimize global patient management. 
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Appendix. Heart failure management evaluation grid
GRID No.
Date:
Department of admission:    Transferred to:    Death during stay:
Name of evaluator:
Title:
Patient identification: first 3 letters     or label:
N° CRITERIA YES NO NA REMARKS
  POSITIVE DIAGNOSIS
1 Clinical examination
  CONVENTIONAL PARACLINICAL INVESTIGATIONS
2 Chest X-ray
3 ECG
4 SPO2 or blood gases
5 TTE or equivalent, place
6 NT pro BNP, place
7 Response to treatment
8 TYPE : systolic or not
  AETIOLOGICAL DIAGNOSIS
9 Aetiology
10 Precipitating factor
11 GLOBAL ASSESSMENT
  GERIATRIC ASSESSMENT IF >75 YEARS
12 MMSE
13 Autonomy
  CO-MORBIDITY
14 Gait
15 Nutritional status
16 Urinary disorders
17 SOCIAL EVALUATION 
  TREATMENT
  DIET AND LIFESTYLE MEASURES
18 TPE
19 Rehabilitation
  MEDICATION
20 Time from admission to treatment
21 Delay with non-invasive ventilation
22 ACEi
23 Beta-blockers
24 Aldactone
25 AIIRA
26 Causal
27 Preventive
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Conclusion
This evaluation shows that there is a possible margin for
progression and invites us to continue this action by making
therapeutic patient education a priority. The implementa-
tion of a healthcare guide in the department, the provision
of an educational assessment as well as the creation of
2 weekly shifts for auxillary medical staff dedicated to edu-
cation is a step in this direction. Other approaches include
forward optimization of medication, in particular by a
wider use of beta-blockers which have been validated in
elderly subjects and are very well tolerated and the deve-
lopment of treatment uptitration. Copies of medical
reports are systematically sent to patients to increase their
involvement. Education and surveillance are complemen-
tary. It is essential to integrate primary care doctors in the
healthcare network. A software application dedicated to
heart failure patients is under evaluation. An annual audit
will be conducted to evaluate this progress.
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